TLDR
- Shares of Novo Nordisk advanced more than 3% following the FDA’s distribution of warning letters to 30 telehealth providers regarding deceptive GLP-1 medication marketing.
- These telehealth firms incorrectly promoted compounded semaglutide and tirzepatide as “generic” alternatives to branded medications such as Wegovy and Zepbound.
- The FDA’s enforcement action marks its second wave of similar warnings, continuing a crackdown initiated in September under Trump administration guidance.
- Recipients of the letters have 15 working days to submit written responses detailing corrective measures for identified violations.
- Analysts at Citi Research emphasized the seriousness of these letters, citing the FDA’s previous DOJ referral of Hims & Hers as evidence of potential consequences.
Shares of Novo Nordisk advanced over 3% during Wednesday’s trading session after federal regulators issued warning letters to 30 telehealth providers for making deceptive claims about compounded GLP-1 medications.
The enforcement action focused on companies marketing compounded semaglutide and tirzepatide using terminology such as “generic Zepbound” or “generic Mounjaro.” These are proprietary names for Eli Lilly’s tirzepatide medications.
Certain companies also marketed these compounds under proprietary trademarks while failing to identify themselves as the compounding entity. According to the FDA, this practice created the false impression that they were the original manufacturers.
The regulatory agency emphasized a crucial distinction: compounded medications lack FDA approval and should not be confused with generic drugs.
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to compound drugs in a way that circumvents FDA’s approval process,” FDA Commissioner Marty Makary said in a statement.
Semaglutide serves as the active compound in Novo Nordisk’s Wegovy and Ozempic products. Tirzepatide powers Eli Lilly’s Zepbound and Mounjaro treatments. Several firms also received citations for deceptive marketing of liraglutide, which Novo Nordisk markets as Saxenda.
Second Round of FDA Action
This enforcement wave represents the FDA’s second coordinated action since launching its regulatory crackdown last September. The initial round targeted major players including Eli Lilly, Novo Nordisk, and telehealth provider Hims & Hers Health.
The ongoing enforcement effort stems from President Trump’s executive directive to strengthen oversight of direct-to-consumer pharmaceutical advertising. According to the FDA, it has distributed thousands of such warning letters over the last six months — exceeding the total volume issued throughout the previous ten years.
Firms receiving warning letters must submit written responses within 15 working days, detailing their plans to remedy the identified violations.
Hims & Hers has emerged as a frequent target in this regulatory push. The FDA issued a warning in February regarding potential enforcement action concerning the company’s $49 compounded weight-loss medication. Novo Nordisk subsequently filed a lawsuit against the company during the same month.
The FDA additionally referred Hims & Hers to the Department of Justice in early February.
What Analysts Are Saying
Analysts at Citi Research characterized the most recent warning letters as particularly significant given the intensifying regulatory landscape.
The investment firm highlighted the DOJ referral as an indicator that more severe penalties may await non-compliant companies.
Citi also observed that Commissioner Makary has separately indicated plans to impose restrictions on active pharmaceutical ingredients utilized in compounded GLP-1 formulations. Such a policy shift would further constrain the compounding market.
The regulatory pressure arrives at a critical juncture, preceding anticipated broad Medicare coverage for GLP-1 medications expected during the second quarter.
Novo Nordisk stock advanced 3.59% during Wednesday’s trading session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
